CN1132820C - 药物的结晶改良体 - Google Patents

药物的结晶改良体 Download PDF

Info

Publication number
CN1132820C
CN1132820C CN988000113A CN98800011A CN1132820C CN 1132820 C CN1132820 C CN 1132820C CN 988000113 A CN988000113 A CN 988000113A CN 98800011 A CN98800011 A CN 98800011A CN 1132820 C CN1132820 C CN 1132820C
Authority
CN
China
Prior art keywords
weak
difluorobenzyl
triazole
carboxamide
moderate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN988000113A
Other languages
English (en)
Chinese (zh)
Other versions
CN1217716A (zh
Inventor
R·波特曼
U·C·霍夫梅尔
A·布克哈德
W·谢尔
M·司泽拉吉维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1132820(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1217716A publication Critical patent/CN1217716A/zh
Application granted granted Critical
Publication of CN1132820C publication Critical patent/CN1132820C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN988000113A 1997-06-10 1998-06-08 药物的结晶改良体 Expired - Lifetime CN1132820C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1404/1997 1997-06-10
CH140497 1997-06-10
CH1404/97 1997-06-10

Publications (2)

Publication Number Publication Date
CN1217716A CN1217716A (zh) 1999-05-26
CN1132820C true CN1132820C (zh) 2003-12-31

Family

ID=4209650

Family Applications (3)

Application Number Title Priority Date Filing Date
CN988000113A Expired - Lifetime CN1132820C (zh) 1997-06-10 1998-06-08 药物的结晶改良体
CNB988056755A Expired - Lifetime CN1159300C (zh) 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途
CNB2004100473675A Expired - Lifetime CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB988056755A Expired - Lifetime CN1159300C (zh) 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途
CNB2004100473675A Expired - Lifetime CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途

Country Status (36)

Country Link
US (6) US6740669B1 (enExample)
EP (2) EP0994864B1 (enExample)
JP (2) JP3672575B2 (enExample)
KR (2) KR100409168B1 (enExample)
CN (3) CN1132820C (enExample)
AR (4) AR012946A1 (enExample)
AT (2) ATE237599T1 (enExample)
AU (2) AU725517B2 (enExample)
BR (2) BR9804946A (enExample)
CA (3) CA2614926C (enExample)
CO (2) CO4940452A1 (enExample)
CY (1) CY2007014I2 (enExample)
CZ (2) CZ292260B6 (enExample)
DE (3) DE69813560T2 (enExample)
DK (2) DK0994864T3 (enExample)
ES (2) ES2197485T3 (enExample)
FR (1) FR07C0037I2 (enExample)
HU (2) HU225153B1 (enExample)
ID (2) ID21014A (enExample)
IL (2) IL125733A (enExample)
LU (1) LU91345I2 (enExample)
MY (2) MY120156A (enExample)
NL (1) NL300284I2 (enExample)
NO (2) NO329315B1 (enExample)
NZ (2) NZ331371A (enExample)
PE (2) PE80999A1 (enExample)
PL (2) PL192114B1 (enExample)
PT (1) PT994864E (enExample)
RU (2) RU2198167C2 (enExample)
SI (2) SI0994864T1 (enExample)
SK (2) SK283734B6 (enExample)
TR (2) TR199801630T1 (enExample)
TW (2) TW403740B (enExample)
UY (1) UY25844A1 (enExample)
WO (2) WO1998056773A1 (enExample)
ZA (2) ZA984967B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
AR040233A1 (es) * 2002-05-31 2005-03-23 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
CA2736703A1 (en) 2008-10-13 2010-04-22 Cipla Limited Process for the preparation of rufinamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) * 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
EP2963023B1 (en) * 2009-09-04 2018-04-18 Tactical Therapeutics, Inc. Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
EP2727914A1 (en) 2010-04-30 2014-05-07 Laboratorios Lesvi, S.L. Polymorph of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-carboxamide
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
PH22568A (en) * 1985-04-18 1988-10-17 Ciba Geigy Ag Fluorinated benzyl triazoles and pharmaceutical compositions containing the same
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
EP0484437A4 (en) 1989-07-27 1994-06-01 Searle & Co Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
CN1072215C (zh) 1995-02-22 2001-10-03 赫彻斯特药品和化学品公司 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
WO1998002423A1 (en) * 1996-07-11 1998-01-22 Novartis Ag Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
HUP0000798A2 (hu) 2000-10-30
NO329314B1 (no) 2010-09-27
HUP0000798A3 (en) 2000-10-30
DE69811500D1 (de) 2003-03-27
TR199801631T1 (xx) 1999-06-21
CZ253398A3 (cs) 1999-04-14
AU8437198A (en) 1998-12-30
CY2007014I1 (el) 2009-11-04
PL330764A1 (en) 1999-05-24
US8076362B2 (en) 2011-12-13
CZ292260B6 (cs) 2003-08-13
AU725528B2 (en) 2000-10-12
CO4940448A1 (es) 2000-07-24
MY120156A (en) 2005-09-30
BR9804947A (pt) 1999-08-24
US20030125568A1 (en) 2003-07-03
ES2192779T3 (es) 2003-10-16
PL192114B1 (pl) 2006-08-31
NL300284I2 (nl) 2007-11-01
HK1028242A1 (en) 2001-02-09
DE69811500T2 (de) 2004-04-01
HUP0002113A2 (hu) 2001-02-28
IL125733A0 (en) 1999-04-11
CA2256013C (en) 2007-10-16
ID27660A (id) 2001-04-19
LU91345I2 (fr) 2007-09-04
CN1298708C (zh) 2007-02-07
CZ292481B6 (cs) 2003-09-17
NO329315B1 (no) 2010-09-27
HU225153B1 (en) 2006-07-28
AU725517B2 (en) 2000-10-12
NO983666D0 (no) 1998-08-11
SI0994863T1 (en) 2003-08-31
CZ253498A3 (cs) 1999-04-14
AR061005A2 (es) 2008-07-30
US20060116520A1 (en) 2006-06-01
CN1217716A (zh) 1999-05-26
EP0994864B1 (en) 2003-04-16
US20040167186A1 (en) 2004-08-26
DE69813560T2 (de) 2004-02-05
CA2256013A1 (en) 1998-12-17
AR061004A2 (es) 2008-07-30
JP3672575B2 (ja) 2005-07-20
DE122007000051I1 (de) 2007-11-08
PT994864E (pt) 2003-07-31
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
DE122007000051I2 (de) 2009-02-19
NZ331370A (en) 2000-08-25
AR012945A1 (es) 2000-11-22
US7750028B2 (en) 2010-07-06
PE80999A1 (es) 1999-09-06
TR199801630T1 (xx) 1999-06-21
CN1259127A (zh) 2000-07-05
SK109398A3 (en) 1998-12-02
PL330798A1 (en) 1999-06-07
CA2614926A1 (en) 1998-12-17
RU2194041C2 (ru) 2002-12-10
TW526195B (en) 2003-04-01
ATE232852T1 (de) 2003-03-15
CY2007014I2 (el) 2009-11-04
US20010037029A1 (en) 2001-11-01
CN1572789A (zh) 2005-02-02
ZA984967B (en) 1999-01-11
HK1028241A1 (en) 2001-02-09
PL191943B1 (pl) 2006-07-31
ZA984966B (en) 1999-01-11
DE69813560D1 (de) 2003-05-22
EP0994863B1 (en) 2003-02-19
WO1998056772A1 (en) 1998-12-17
BR9804946A (pt) 1999-08-24
SI0994864T1 (en) 2003-10-31
DK0994863T3 (da) 2003-05-26
AR012946A1 (es) 2000-11-22
KR19990087835A (ko) 1999-12-27
JP2000516259A (ja) 2000-12-05
EP0994863A1 (en) 2000-04-26
TW403740B (en) 2000-09-01
IL125732A0 (en) 1999-04-11
KR100409168B1 (ko) 2004-01-31
FR07C0037I1 (enExample) 2007-08-17
ID21014A (id) 1999-04-08
CA2256015C (en) 2008-06-03
CA2614926C (en) 2010-02-09
KR100425656B1 (ko) 2004-05-17
AU8437298A (en) 1998-12-30
JP2000516258A (ja) 2000-12-05
UY25844A1 (es) 2001-08-27
KR19990087836A (ko) 1999-12-27
EP0994864A1 (en) 2000-04-26
NZ331371A (en) 2000-08-25
HK1028031A1 (en) 2001-02-02
SK283685B6 (sk) 2003-12-02
DK0994864T3 (da) 2003-07-21
CA2256015A1 (en) 1998-12-17
HUP0002113A3 (en) 2002-09-30
US6455556B2 (en) 2002-09-24
ES2197485T3 (es) 2004-01-01
NO983667L (no) 1998-12-17
NO983666L (no) 1998-12-17
ATE237599T1 (de) 2003-05-15
PE79799A1 (es) 1999-09-03
RU2198167C2 (ru) 2003-02-10
MY125854A (en) 2006-08-30
LU91345I9 (enExample) 2018-12-31
US6740669B1 (en) 2004-05-25
US20100310655A1 (en) 2010-12-09
JP3672574B2 (ja) 2005-07-20
FR07C0037I2 (enExample) 2008-05-16
IL125732A (en) 2002-12-01
CO4940452A1 (es) 2000-07-24
CN1159300C (zh) 2004-07-28
IL125733A (en) 2002-12-01
SK109498A3 (en) 1998-12-02
HU226107B1 (en) 2008-04-28
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
CN1132820C (zh) 药物的结晶改良体
US12421227B2 (en) Ribociclib salts and solid state forms thereof
CN100345840C (zh) 毒蕈碱性受体拮抗剂的稳定水合物
EP3430004B1 (en) Solid state forms of nilotinib salts
EP3327012B1 (en) Crystalline forms of bilastine and preparation methods thereof
JP2009235088A (ja) ５−ヒドロキシ−１−メチルヒダントイン結晶の製造方法
EP0683167A1 (en) Terazosin monohydrochloride and processes and intermediate for its production
CN1214029C (zh) 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物
US20120220655A1 (en) Crystalline forms of fesoterodine fumarate and fesoterodine base
JPH09124644A (ja) テラゾシン結晶性ポリモルフ及びその製薬組成物
HK1020051A (en) Crystal modification of a pharmaceutical agent
RU2772222C2 (ru) Кристаллические формы биластина и способы их получения
JPH09301972A (ja) Ｎ−（１−置換−アザシクロアルカン−３−イル）カルボキサミド誘導体及びそれを含有する医薬組成物
HK1028031B (en) Crystal modification of 1-(2,6-difluorobenzyl)-ih-1,2,3-triazole-4-carboxamide and its use as antiepileptic
WO2021046014A1 (en) Solid state forms of pamiparib and process for preparation thereof
HK1028241B (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
MXPA98006951A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CX01 Expiry of patent term

Granted publication date: 20031231

CX01 Expiry of patent term